From TekinHealthHealthcare Tech Field Notes

The US Department of Labor finalized its pharmacy benefit manager fee disclosure rule on October 29, 2026. It requires PBMs and their affiliated brokers and consultants to disclose direct and indirect compensation to large self-insured employer group health plans. The rule includes initial and semiannual disclosures and audit rights for plan fiduciaries, plus an exemption for fiduciaries when a PBM fails to disclose. Trade reports say it applies to plan years beginning on or after July 1, 2027. It implements transparency provisions Congress enacted in the Consolidated Appropriations Act, 2026.

Why it's notable: Self-insured employers will get a clearer view of how PBMs are paid, including rebates and spread pricing. That could change formulary and drug-cost decisions that affect clinics and their patients.

NYU Langone Health and OpenEvidence announced on October 29, 2026 that OpenEvidence will be built into NYU Langone's Epic EHR as "Patient Aware Clinical Intelligence." Clinicians can ask clinical questions in natural language and get answers drawn from peer-reviewed literature with patient context, without leaving Epic. It covers the system's hospitals, ambulatory network and Family Health Centers, and trainees at its medical schools. NYU Langone reports about 12.4 million outpatient visits a year.

Why it's notable: A large academic system is putting a clinician-facing AI reference tool inside the chart, with patient context, rather than leaving it as a separate app. Other systems have made similar moves, and this one shows the model spreading.

On Oct. 26 the Office of the National Cyber Director and HHS launched Project Lifeline 250 with South Carolina's critical infrastructure cybersecurity initiative. It is a six-month pilot offering rural hospitals free cybersecurity help, with industry partners including Cisco, Cyera, Microsoft, Trellix and Zscaler. It follows a July cyberattack on South Carolina health system AnMed that disrupted access to records for weeks. Officials did not name participating hospitals or say how many will take part.

Why it's notable: Small rural hospitals often lack security staff and budget, and attacks can force them onto paper records. The pilot is a federal test of a template that could be extended to other states.

University of Minnesota and Brown University researchers (Hannah Neprash and Michael Barnett) compared traditional Medicare use of WISeR-targeted services in the six pilot states with use in all other states. The data came from Epic Cosmos, and the study covers the two years before the January 2026 launch and the first six months after. Epidural steroid injections, the highest-volume service, fell about 15%, and other targeted services fell about 20%. Services that were slated for the pilot but never implemented showed no significant change.

Why it's notable: This is the first outside evidence that the AI-assisted prior authorization pilot cuts utilization in Arizona, New Jersey, Ohio, Oklahoma, Texas and Washington. The effect shrank over time: epidural injections went from about -21% in Q1 to about -9% in Q2. The authors say they cannot tell whether the avoided care was unnecessary or needed, which is the question clinics and patients most care about.

UnitedHealthcare has expanded Avery, its generative AI assistant, to about 21 million members across commercial, Medicare and Medicaid plans. Avery launched in March to roughly 6.5 million employer-plan members and 160,000 Medicare Advantage members. Members can use it in the UnitedHealthcare app to ask about benefits, costs, claims and in-network providers, and it can phone physician offices to book appointments for them. The company says Avery resolves about 90% of member interactions without a human, and hands the rest to a human advocate.

Why it's notable: A large payer is putting an AI agent that phones provider offices in front of tens of millions of members, so practices may field more calls from an automated caller. The 90% resolution figure is the insurer's own and has not been independently verified.

On Oct. 26, ONC finalized its HTI-5 deregulatory rule. It removes 14 of the 60 health IT certification criteria and revises seven. It also drops the requirement that certified EHRs show clinicians the source attributes behind AI and other predictive decision-support tools. ONC says the rule saves about $1.55B in net present value. The C-CDA and Direct sunset moves to 2030 and vendors must still publish their public FHIR endpoint URLs. Proposed changes to information blocking exceptions and disincentives were not finalized and remain under review.

Why it's notable: Certified EHRs that clinics use will carry fewer built-in AI transparency, privacy and security requirements, and ONC says algorithm safety oversight belongs with the FDA and nondiscrimination rules. Critics argue this weakens safety protections, while the rule also steers vendors toward FHIR-based exchange.

Pathos AI closed a $237 million Series E at a valuation of about $3 billion, led by Bristol Myers Squibb. Endpoints reports the round came in below the roughly $300 million the company had sought. The company says the money will expand its AI drug-development platform and advance its oncology pipeline. STAT reports Tempus AI is supplying new datasets and that a collaboration with BMS will first focus on Alzheimer's treatments, taking Pathos beyond oncology.

Why it's notable: A large pharma company leading the round, and a data supplier in Tempus joining it, shows AI drug developers building ties with the data and drug companies that run clinical trials. The planned move from oncology into neurology widens the platform's reach.

Eko Health launched the CORE 300, a stethoscope that switches between analog listening and digital modes by twisting the chestpiece. It has adult and pediatric diaphragms. Eko says the FDA 510(k) clearance came in July, and its cleared AI flags suspected structural heart murmurs from recordings. The device lists at $199, and the AI analysis needs an Eko+ subscription at $119.99 a year.

Why it's notable: It puts AI-assisted murmur screening into an ordinary-looking stethoscope at a lower price than earlier Eko models. That could make the screening practical for primary care and pediatric clinics that skipped digital devices.

On Oct. 21, 2026, CMS and the Department of Labor announced that five large employers signed a statement of support for extending electronic prior authorization improvements to self-funded health plans. The employers are Amazon, Google, Meta, Oracle and Axon Enterprise. The statement asks the insurers and third-party administrators that joined the 2025 federal prior authorization pledge to make the same upgrades available to self-insured plan sponsors. The employers did not commit to reducing prior authorization in their own plans. They said any such changes would be weighed against their ERISA fiduciary duties and decided plan by plan.

Why it's notable: More than half of Americans are covered through self-funded employer plans, which the federal electronic prior authorization rules for Medicare Advantage, Medicaid, CHIP and ACA plans do not reach. The statement is voluntary, but it is the first push from large employers to bring those patients into the prior auth fixes.

At its Open@Epic conference on Oct. 21, Epic announced Connectors, which let third-party apps plug into its AI agents: Emmie (patient-facing), Art (clinician-facing) and Penny (revenue cycle and operations). Connectors also work with custom agents that health systems build in Epic's no-code Agent Factory. Examples given include an ambulance app feeding arrival times to an emergency department and a hospital dietary app taking meal orders through Emmie. Fierce Healthcare reports that developer-built Connectors will be available through Epic Showroom starting in March 2027.

Why it's notable: Most health systems run their AI tools inside Epic, so how outside vendors connect to Epic's agents will shape which tools they can adopt. It is a defined route for vendors beyond one-off integrations, though it is not available until 2027.

Elucid received FDA 510(k) clearance for FFR-IQ, software that estimates fractional flow reserve from coronary CT angiography and uses plaque composition data from its PlaqueIQ product. The company says the clearance rests on the ELUCIDATE trial (491 vessels, 347 patients), where it reported 92.2% sensitivity and 93.1% specificity against invasive FFR. Elucid plans to combine FFR-IQ and PlaqueIQ in a single platform. Trade press reports it as the third commercially available FFR-CT product in the US, after HeartFlow and Keya Medical.

Why it's notable: A new vendor in non-invasive FFR-CT adds competition in a market long dominated by HeartFlow, and may offer cardiology and imaging programs another way to assess ischemia from a single CT scan. The accuracy figures are the company's own.

The FDA approved Edwards Lifesciences' Pascal Precision system for transcatheter edge-to-edge repair of the tricuspid valve, announced Oct. 21, 2026. The indication is symptomatic severe tricuspid regurgitation in patients who remain symptomatic on optimal medical therapy, are at intermediate or higher surgical risk, and are judged suitable for the procedure by a multidisciplinary heart team. The approval rests on the CLASP II TR pivotal trial, with one-year results due at TCT 2026. The device was already approved for degenerative mitral regurgitation in 2022.

Why it's notable: It adds a second transcatheter edge-to-edge option for tricuspid disease alongside Abbott's TriClip, giving heart teams a choice for patients who are poor candidates for surgery. Edwards says it is now the only company offering both repair and replacement for the mitral and tricuspid valves in the US.

CMS proposed a rule on October 16, 2026 requiring Medicare Advantage plans to verify and update provider directory listings at least every 90 days, publicly report directory accuracy scores, and cap enrollee cost-sharing at in-network rates when a directory wrongly lists a provider as in-network. The same proposal would limit pharmacy benefit managers handling Part D drugs to flat, itemized service fees that cannot depend on drug prices or rebates, starting with contract year 2028. CMS Administrator Mehmet Oz said the changes are meant to give enrollees more reliable directory information and stronger financial protections. The agency is accepting public comments for 60 days after the rule publishes in the Federal Register.

Why it's notable: Inaccurate 'ghost network' directories and rebate-driven PBM compensation are long-running sources of billing disputes and network confusion for practices and patients; a finalized rule would change what MA plans must disclose and how PBMs get paid starting in 2028.

The FDA granted 510(k) clearance to SimBioSys's TumorSight Risk, cloud-based software that analyzes a patient's existing breast MRI along with pathology and clinical factors (age, race, tumor stage, nodal stage, histologic grade) to estimate the risk of breast cancer recurrence at 5 and 10 years. It is cleared for adult women with hormone receptor-positive, HER2-negative stage I-IIIA breast cancer, a subtype representing about 75% of US breast cancers. The software produces a 0-100 score and a high-, intermediate- or low-risk classification, with results available before surgery and no extra scan or tissue shipment needed. The company says clearance was supported by a blinded, multi-institutional validation study of more than 2,100 patients from Mayo Clinic, Emory University, Stanford Medicine and Mercy Medical Center Cedar Rapids, where each 10-point increase in score corresponded to a 22% rise in relative recurrence risk.

Why it's notable: It gives oncologists an FDA-cleared, MRI-derived recurrence-risk estimate from imaging most patients already have, potentially informing treatment-intensity decisions for the most common breast cancer subtype without added biopsies or tests.

Epic announced Prescription Marketplace, a tool built into its EHR that will let clinicians and patients compare a medication's insurance price against cash prices at participating pharmacies before a prescription is sent. Amazon Pharmacy, Mark Cuban's Cost Plus Drugs, Costco and Eli Lilly's LillyDirect have committed to sharing their pricing data, and Epic says any pharmacy can join. The company plans to launch the feature in summer 2027.

Why it's notable: Prescribers using Epic could surface cheaper cash-pay options at the point of care instead of patients discovering a lower price only after leaving the pharmacy counter, addressing a cost barrier that Epic says causes over 40% of US adults to skip medications.

Centene announced on October 13, 2026 that it will launch a National Performance-Based Gold Card Program in November, exempting about 160,000 providers nationwide from routine prior authorization on certain outpatient services based on their approval history, documentation quality and compliance record. The program spans Centene's commercial, Medicare Advantage and Medicaid lines of business. Qualifying providers must still submit a pre-notification before rendering care but won't have to wait for a prior-authorization decision first. The company says it expects to expand the list of covered services and eligible providers over time.

Why it's notable: Prior authorization delays are one of the most common administrative complaints from physician practices, and a gold-card exemption spanning 160,000 providers across all of a major insurer's business lines removes a meaningful share of that paperwork for qualifying clinics.

Stryker agreed to make a preferred equity investment of about $400 million in UK surgical robotics maker CMR Surgical. The stake gives Stryker an exclusive option to acquire all of CMR's equity later. Stryker would become the exclusive US sales agent for the Versius soft-tissue robot, while CMR keeps development and commercialization outside the US. The deal is subject to regulatory approvals and customary closing conditions.

Why it's notable: It gives Stryker a route into soft-tissue robotic surgery, a market it has not served, where Intuitive dominates and Medtronic and J&J are building entrants. Hospitals weighing robot purchases may see another large vendor in the field.

Suki, which sells an AI ambient documentation and medical-coding platform used by more than 450 healthcare organizations, raised a $90 million Series E led by Healthier Capital, with Crosslink Capital and Hercules Capital joining existing investors Hedosophia, Venrock, Flare Capital Partners and Philips. The company says it is projecting $60-80 million in revenue this year, and total funding now exceeds $250 million. Suki plans to use the money to build agentic features that handle post-visit administrative tasks such as setting up referrals and scheduling, beyond its existing note-taking and coding tools.

Why it's notable: A large new round for an established ambient-scribe vendor shows investors still see room to grow in AI documentation, and signals the category is expanding from note-taking into automating more of the administrative work around a visit.

Northwestern Medicine began giving clinicians single sign-on access to OpenEvidence's AI-driven clinical search tool directly inside its Epic EHR starting October 8, 2026. Doctors, nurses and pharmacists can launch the tool without re-entering credentials to check drug dosing and interactions, review current guidelines, and get answers cited to peer-reviewed literature including NEJM and JAMA. The health system describes it as the first phase of a broader push to deploy clinical AI safely across the bedside workflow.

Why it's notable: Embedding AI-driven evidence lookup inside the EHR, rather than as a separate app, removes a step clinicians have to take mid-visit and extends access beyond physicians to the full care team.

Abridge and the University of Texas System announced an enterprise-wide agreement on October 8, 2026, giving UT institutions — including UT Southwestern, MD Anderson, UTHealth Houston, UT Health San Antonio and others — systemwide access to its AI clinical-documentation platform, coordinated through the state-funded UT REAL Health AI initiative. The deal follows a 2025 pilot across five locations and more than 50 specialties that the companies say saw a 73% increase in clinicians recording encounters and an 80% increase in monthly AI-generated notes over the past year. UT's hospitals and clinics handle nearly 11.7 million outpatient visits and over 2 million hospital days annually.

Why it's notable: It extends ambient AI documentation to one of the largest academic health systems in the country and sets up future use for care-gap identification, payer workflows and clinical trial matching, signaling how far scribe tools are moving beyond note-taking.

General Medicine, a direct-to-consumer healthcare marketplace founded by PillPack alumni TJ Parker and Elliot Cohen with former Amazon executive Ashwin Muralidharan, raised a $120 million Series B led by Andreessen Horowitz. Eli Lilly and Mercy Health (through Granger Management) joined the round alongside Matrix, VXI Capital and BoxGroup, bringing the company's total funding to $152 million. The company says its platform now lists more than 2,900 purchasable healthcare products and services, including primary and urgent care, chronic condition management, specialist e-consults, prescriptions, lab testing and care coordination, available with or without insurance.

Why it's notable: A pharmaceutical manufacturer and a health system are both financially backing a retail-style storefront for buying care directly, a sign that incumbents see consumer-directed, price-transparent care shopping as a channel worth investing in rather than just competing against.

Abbott announced on October 5, 2026 that FDA approved new capabilities for its CardioMEMS HF System, an implanted pulmonary artery pressure sensor used to manage heart failure. The update adds a CardioGuide HF App that lets patients view their own pressure readings on a smartphone for the first time, plus a Dynamic Treatment Plan feature that lets clinicians pre-set medication-adjustment instructions the app sends to patients automatically when their readings change. Abbott says both features will roll out later in 2026.

Why it's notable: Gives heart failure patients direct visibility into a measurement care teams already use to guide treatment, and lets clinicians push pre-approved medication changes to CardioMEMS-enrolled patients without a separate office visit or call.

On October 5, 2026, Utah's Office of Artificial Intelligence Policy approved a one-year pilot in which Nolla Health's app scans a patient's face, scores acne severity, and prescribes from a list of eight topical treatments without a clinician writing the prescription. It is limited to adults with mild-to-moderate acne; the state waived its rule that a prescriber be a licensed physician for this narrow case. Physicians review the first 100 prescriptions before they go to a pharmacy and the next 400 weekly after the fact, then a sample of at least 10% each month, with a reviewer appointed by the Utah Medical Licensing Board. The same day the office approved two more company pilots, Expect Fitness for AI-supported postpartum physical therapy and August AI for prescription refills, and signed master agreements with Intermountain Health and University of Utah Health covering data privacy, AI governance and reporting so both systems can test AI tools under the sandbox.

Why it's notable: Nolla says it is the first program in the US to let AI issue initial prescriptions rather than renewals, a step beyond Utah's January refill pilot, and the master agreements bring Intermountain Health and University of Utah Health into the same sandbox.

Heidi Health launched Heidi II, moving its ambient scribe platform from drafting notes to having AI agents carry out the administrative follow-up work those visits generate: pre-charting schedules, auditing referral correspondence, and flagging overdue screenings and immunizations across a clinic's calendars, EHR, portals and email. Clinician approval is required before the agents execute clinical decisions or communications. The company says its platform already surfaces about 10 million follow-up tasks a week across 2.8 million weekly patient interactions in 190 countries; Heidi II began rolling out September 29 in English and French, and is not yet available in the UK or EU.

Why it's notable: Ambient scribes have mostly stopped at writing the note and leaving the resulting to-do list for clinicians to clear themselves; automating that follow-through, under supervision, targets a large chunk of the administrative load clinics cite as a driver of burnout.

The Health Resources and Services Administration said on October 1, 2026 that it approved 10 drug manufacturers, including AbbVie, Amgen, AstraZeneca, Pfizer, Merck and Teva, to take part in its revised 340B Rebate Model Pilot Program covering 21 outpatient drugs. Instead of giving 340B hospitals and clinics an upfront discount at purchase, participating manufacturers will pay rebates after the fact once a claims-verification platform confirms a patient was eligible; the pilot launches January 1, 2027 and runs at least a year, with HRSA due to publish a performance evaluation by April 30, 2028. HRSA says the model is meant to cut fraud and improve transparency in the discount program; the American Hospital Association says it will impose new administrative and financial burdens on safety-net providers and is weighing ways to stop it.

Why it's notable: 340B discounts are a major source of revenue for safety-net hospitals, rural providers and community health centers, so switching from upfront discounts to after-the-fact rebates changes cash flow and billing work for any clinic enrolled in the program.

The FDA approved Edwards Lifesciences' AUTUS Size-Adjustable Valve on October 1, 2026, a surgically implanted pulmonary heart valve for children with congenital pulmonary valve disease. The valve can be implanted at about 13 mm, sized for a toddler, and later widened with a balloon catheter to about 22 mm as the child grows, and it is the first FDA-approved heart valve to use polymeric leaflets instead of animal-derived tissue. The company says its pivotal study met its primary safety and effectiveness endpoints, with 100% of patients free of device-related complications through 30 days and no valve reinterventions through six months.

Why it's notable: Children with congenital heart defects have typically needed repeated open-heart surgeries to replace fixed-size valves as they grow; a valve that expands in place without replacement could cut the number of operations these patients face over a lifetime.

The Senate passed the Health Care Cybersecurity and Resiliency Act of 2026 (S. 3315) by unanimous consent on September 30, 2026. The bipartisan bill, sponsored by Sens. Bill Cassidy, Maggie Hassan, John Cornyn and Mark Warner, would require HHS and the Cybersecurity and Infrastructure Security Agency to coordinate on responding to health sector cyberattacks, require private health care entities to adopt baseline cybersecurity practices such as multifactor authentication aligned with NIST frameworks, fund cybersecurity grants including for rural clinics, and add a requirement to disclose the number of people affected in breach notifications. The bill now goes to the House of Representatives.

Why it's notable: If it becomes law, the bill would set new minimum cybersecurity practices and incident-response obligations for hospitals and clinics at a time when ransomware and data breaches are already costly and disruptive for health systems, though it still needs House passage and a presidential signature.

Grindr agreed to acquire PurposeMed, the Canadian parent company of PrEP telehealth provider Freddie, for $250 million upfront ($190 million cash, $60 million stock) plus up to $70 million in performance-based payments, with the deal expected to close in the fourth quarter of 2026. The acquisition launches a new business line, Grindr Health, which will route Grindr's dating-app users into PrEP prescribing, STI testing and medication delivery through Freddie's existing telehealth and pharmacy network. Freddie currently serves roughly 55,000 patients across the US and Canada and projects more than $80 million in 2026 revenue. Grindr says it eventually plans to add erectile dysfunction and GLP-1 prescribing to the platform.

Why it's notable: It is one of the largest moves yet by a consumer tech platform directly into prescribing and medication delivery, and could meaningfully expand PrEP access and testing volume funneled to telehealth and sexual health providers.

The federal Advanced Research Projects Agency for Health awarded the University of Vermont up to $38 million, the largest research award in the school's history, to build AI models that create a digital "twin" of a critically ill patient's immune and inflammatory state from blood samples and physiological monitoring. Led by UVM trauma surgeon Dr. Gary An under ARPA-H's CIRCLE program, the team will use the twin to test candidate treatments virtually before giving them to the patient, with data collection sites at Wake Forest, WashU Medicine and the University of Alabama at Birmingham. The five-year award is structured in milestones; researchers must show by year three that the digital twin can accurately replicate a patient's immune response and predict outcomes to unlock the full funding, and the team believes success could cut ICU length of stay by at least 25%.

Why it's notable: It is a large, concrete federal bet on using AI to personalize ICU treatment decisions rather than just document them, and a positive result could change how intensivists choose therapies for the sickest patients years before any product reaches the bedside.

Gov. Gavin Newsom signed a package of AI bills on September 30, 2026, including AB 1979 and SB 503. AB 1979, sponsored by the California Nurses Association, guarantees licensed clinicians can exercise their own professional judgment over care decisions informed by AI clinical-decision-support tools and extends medical confidentiality protections to patient data accessed through health chatbots, with exemptions for AI used in documentation. SB 503 requires developers and deployers of medical clinical decision support systems to make reasonable efforts to identify and mitigate known or foreseeable bias in their systems. The same day, Newsom vetoed separate bills that would have protected clinicians from retaliation for overriding AI recommendations and further restricted AI in mental health care.

Why it's notable: California is the first state to legally guarantee clinicians the final call over AI-informed care decisions and to require bias monitoring of clinical decision-support software, a template compliance teams at other health systems are likely to watch.

CMS finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, a mandatory rule that recalculates rebates for certain separately payable Medicare Part B drugs and biologics using prices paid in economically comparable countries. The model covers drugs typically administered in clinical settings for conditions like cancer, autoimmune disease and arthritis, applying to roughly 25% of Original Medicare beneficiaries in randomly selected geographic areas; it excludes biosimilars, orphan drugs and cell and gene therapies. CMS's performance period runs April 2027 through March 2032, and the agency now projects about $440 million in net Part B savings over the seven-year payment period, down sharply from the $8.4 billion it had projected when the rule was proposed.

Why it's notable: Hospitals and physician offices that administer infused or injected drugs now have a federal rule, not just a proposal, that ties part of their Medicare Part B drug reimbursement to international prices, adding a new variable to drug acquisition and billing planning. Hospital groups had pushed to make participation voluntary and warned that manufacturers could respond by raising the acquisition prices hospitals pay, so how drugmakers react will matter as much as the rule itself.

EliseAI raised $350 million led by Andreessen Horowitz and Bessemer Venture Partners, with Ontario Teachers' Pension Plan, Sapphire Ventures and Navitas Capital also participating, taking its valuation to $4 billion, the company announced September 29, 2026. Its healthcare division automates the administrative patient journey for specialty physician groups: inbound calls, referral intake, scheduling, insurance eligibility verification, pre-visit chart prep and post-visit follow-up, built on the same agentic platform (recently extended with an AI teammate called Apollo) that the company originally developed for apartment leasing. EliseAI says it now handles about 5 million calls a month across its housing and healthcare businesses combined but does not disclose healthcare-specific revenue.

Why it's notable: It is one of the largest funding rounds this year for AI that automates clinic front-office work rather than clinical documentation, and the money is earmarked partly to grow healthcare-specific engineering and deployment teams. For clinic operators, it signals more investment flowing into agentic tools aimed at referral, scheduling and insurance-verification bottlenecks, the administrative load that competes with patient care for staff time.

DreaMed Diabetes received FDA 510(k) clearance for MODI, a mobile app that uses continuous glucose monitor data to generate insulin dosing recommendations for adults with Type 2 diabetes. The company says it is the first FDA-cleared app that can automatically adjust doses for patients on both basal-only insulin and more complex multiple daily injection (basal-bolus) regimens, rather than basal-only tools alone. Dose changes can be made between office visits without a clinician approving each individual adjustment.

Why it's notable: Type 2 patients on multi-injection insulin regimens are common and hard to titrate safely between visits, so extending automated dosing support to this group could ease a significant chronic-care workload for primary care and endocrinology.

The Cigna Group announced a partnership with OpenAI to build AI into clinical workflows at Cigna Healthcare and its Accredo Specialty Pharmacy, starting with cancer care. The first tool gives oncology nurses and case managers an AI-enabled interface that pulls together a patient's clinical, pharmacy, behavioral and benefits data into one view, along with patient-reported information like side effects and preferences. Cigna says the goal is to help clinical teams spot needs and coordinate support between physician visits, under human and clinician oversight. The companies plan to expand the collaboration to other conditions over time.

Why it's notable: It puts a large national payer's AI push directly into oncology case management workflows that clinics and specialty pharmacies already touch, rather than just member-facing chat.

The Blue Cross Blue Shield Association analyzed claims data from 2023 to 2025 and found that as hospitals adopted AI coding tools — ambient scribes and automated chart-scanning software that flag secondary diagnoses — more patients were coded as medically complex without a matching change in the care actually delivered. BCBSA estimates this added $942 million in costs across its plans, with $653 million of that traced to more than 55,000 claims pushed into higher-paying complexity tiers by added secondary diagnoses, averaging about $11,000 per case. BCBSA says the figure excludes cases where documentation reflected genuinely new care. Hospital groups dispute the framing, saying patients are sicker and that AI tools are correcting years of underdocumented complexity.

Why it's notable: Health systems are adopting the same ambient-documentation and coding AI at scale (e.g., the VA's Abridge contract), and a major payer is now using claims data to contest how those tools shift reimbursement — a dispute that will shape audits and contract terms for any practice using AI scribing or coding software.

Precision Neuroscience closed an oversubscribed $250 million Series D led by Pershing Square, the Ackman Oxman Institute and an undisclosed life-sciences investment fund, bringing its total raised since founding in 2021 to $430 million. Its Layer 7 Cortical Interface, a thin-film array of 1,024 electrodes that sits on the brain's surface without penetrating tissue, received FDA 510(k) clearance in 2025 for implantation up to 30 days. The company says it has completed more than 100 patient procedures across 18 medical institutions, including Mount Sinai, University of Chicago Medicine and Penn, and has a commercial partnership with Medtronic. Precision says the new funding will expand its clinical program and support further FDA review.

Why it's notable: It's one of the largest rounds yet for a brain-computer interface company, and one of the few with an FDA-cleared implant already in hospital use rather than confined to research settings, signaling BCI is moving from experimental to clinical faster than expected.

Meta announced Hearing Enhancement, a software feature for its Meta-branded smart glasses (not the Ray-Ban Meta line, at least initially) that amplifies and processes environmental sound for adults with mild to moderate hearing loss. The underlying software, Hearing Assist, received FDA 510(k) clearance on July 13, 2026, as a Class II over-the-counter self-fitting hearing aid, using Apple's Hearing Aid Feature as its predicate device. Users set it up and self-fit through a smartphone app with no clinic visit or prescription required; the feature costs $149.99 as an add-on, is included with a Meta One subscription, and is HSA/FSA eligible.

Why it's notable: It puts an FDA-cleared hearing aid into a mainstream consumer device for the first time, extending the OTC hearing aid model started by Apple to another large tech platform and giving more patients with mild-to-moderate hearing loss a self-service path that bypasses an audiologist visit.

Colorado-based Enveda raised a $311 million Series E led by Catalio Capital Management, reportedly at a $2 billion valuation. That brings its total funding to more than $845 million. Enveda uses AI to identify and rank molecules from plants and microbes as drug candidates. It has three programs in human testing: ENV-294 for atopic dermatitis and asthma, now in Phase 2a; ENV-308 for obesity; and ENV-6949, which targets TL1A for inflammatory bowel disease.

Why it's notable: This is one of the largest private rounds this year for an AI drug-discovery company. It gives Enveda funding for several mid-stage trials, a real test of whether AI-found compounds hold up in patients.

The Department of Veterans Affairs selected Abridge under a five-year, multi-award enterprise contract with a ceiling of $775.72 million to provide ambient AI scribes. Knowtex also holds a seat on the contract. The VA began piloting ambient scribes from both vendors in October 2025. The tool is now available to primary care, behavioral health, physical medicine and rehabilitation, and medical and surgical specialty clinicians at more than 75 VA medical centers. Abridge says its scribe runs on both the VA's legacy VistA/CPRS system and the new Oracle Health federal EHR.

Why it's notable: This is one of the largest single ambient AI deployments in US healthcare, and it spans two different EHR platforms. How it goes at the VA will be a reference point for other large systems deciding whether to scale AI scribes.

Melbourne-based Heidi Health raised $340 million: a $100 million Series C led by Blackbird at a $900 million valuation, plus $240 million in growth investment from General Catalyst. The company says its tools support 2.8 million patient visits a week in 190 countries. Its customers include Beth Israel Lahey Health and NHS England Midlands, which Heidi calls the largest clinical AI procurement in NHS history. Heidi plans to move from documentation into supervised, agent-style tasks it calls an AI Care Partner.

Why it's notable: This is one of the largest rounds yet for an ambient-scribe company outside the US leaders. It shows scribe vendors racing to take on more clinical and administrative work, which clinics will see in upcoming product and pricing choices.